| Disease | EXERTS FAVORABLE EFFECTS ON THE LIPID PROFILE.
WAS NO SIGNIFICANT DIFFERENCE IN LDL OXIDIZABILITY OR PLASMA LIPID PEROXIDES FOLLOWING PYC SUPPLEMENTATION. HENCE, FOLLOWING ORAL SUPPLEMENTATION IN HUMANS, PYC SIGNIFICANTLY INCREASES ANTIOXIDANT CAPACITY OF PLASMA, AS DETERMINED BY ORAC., AND
ADDITION TO ITS ANTIOXIDANT EFFECTS, PYC SIGNIFICANTLY REDUCED LDL-CHOLESTEROL LEVELS AND INCREASED HDL-CHOLESTEROL LEVELS IN PLASMA OF TWO-THIRDS OF THE SUBJECTS. WHILE THE LDL CHANGES REVERSED DURING WASHOUT, THE HDL INCREASE DID NOT. THERE
EFFECT OF PYC WAS DEMONSTRATED BY A SIGNIFICANT INCREASE IN OXYGEN RADICAL ABSORBANCE CAPACITY (ORAC) IN PLASMA THROUGHOUT THE SUPPLEMENTATION PERIOD (P<0.05). THE ORAC VALUE RETURNED TO BASELINE AFTER THE 4-WK WASHOUT PERIOD. MORE-OVER, IN
3 AND 6 WK OF SUPPLEMENTATION, AND AGAIN AFTER A 4-WK WASHOUT PERIOD. AFTER 6 WK OF SUPPLEMENTATION WITH PYC, A SIGNIFICANT INCREASE IN PLASMA POLYPHENOL LEVELS WAS DETECTABLE, WHICH WAS REVERSED AFTER THE 4-WK WASHOUT PHASE. THE ANTIOXIDANT
THE AIM OF THIS STUDY WAS TO TEST THE EFFECT OF PYC SUPPLEMENTATION OF MEASURES OF OXIDATIVE STRESS AND THE LIPID PROFILE IN HUMANS. TWENTY-FIVE HEALTHY SUBJECTS RECEIVED PYC (150 MG/D) FOR 6 WKS. FASTING BLOOD WAS COLLECTED AT BASELINE, AFTER |